--- title: "Hong Kong Stock Movement: IMPACT THERAP-B rebounds 16.16%, can the market sentiment recovery be sustained? The volatility of newly listed stocks raises concerns" type: "News" locale: "en" url: "https://longbridge.com/en/news/287323885.md" description: "IMPACT THERAP-B rose 16.16%; CSPC Pharmaceutical Group rose 4.50%, with a transaction volume of HKD 686 million; Heng Rui Medicine fell 1.68%, with a transaction volume of HKD 186 million; China National Pharmaceutical Group fell 1.14%, with a transaction volume of HKD 174 million; Hansoh Pharmaceutical fell 1.41%, with a market value of HKD 203.9 billion" datetime: "2026-05-22T07:32:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287323885.md) - [en](https://longbridge.com/en/news/287323885.md) - [zh-HK](https://longbridge.com/zh-HK/news/287323885.md) --- # Hong Kong Stock Movement: IMPACT THERAP-B rebounds 16.16%, can the market sentiment recovery be sustained? The volatility of newly listed stocks raises concerns **Hong Kong Stock Movement** IMPACT THERAP-B rose 16.16%. Based on recent key news: 1. On May 21, several newly listed Hong Kong stocks plummeted. IMPACT THERAP-B dropped over 16%, attracting market attention. On that day, Yifei Technology fell over 23%, Xizhi Technology dropped over 18%, Topcon CNC fell over 15%, and Guomin Technology dropped over 1%. 2. On May 22, market expectations for a rebound in IMPACT THERAP-B increased, leading to a rise in stock price. Investors believed that the previous day's decline was excessive and rushed to buy the stock. 3. Recently, the overall volatility in the Hong Kong stock market has been significant, with newly listed stocks showing particularly notable performance. Investor sentiment has intensified, leading to sharp fluctuations in stock prices. Newly listed Hong Kong stocks have shown significant volatility recently, and investors should exercise caution. **Stocks with High Trading Volume in the Industry** Stone Pharmaceutical Group rose 4.50%. Based on recent key news: 1. On May 22, Stone Pharmaceutical Group announced that its budesonide enteric-coated capsules received drug registration approval from the National Medical Products Administration. This approval enhances the company's product line in the field of kidney disease treatment and improves market competitiveness. 2. On May 22, UBS released a report upgrading Stone Pharmaceutical Group's rating from Neutral to Buy, with a target price of HKD 10.9. UBS pointed out that Stone's leading position in AI drug development has not yet been fully reflected in its valuation, and the company is expected to see organic revenue growth return by 2026. 3. On May 21, Stone Pharmaceutical Group repurchased 1.3 million shares for a total amount of HKD 3.08 million. This move demonstrates the company's confidence in its own value, which may boost investor confidence. The prospects for AI research and development in the pharmaceutical industry are broad, with significant capital inflow. Hengrui Medicine fell 1.68%. Based on recent key news: 1. On May 19, Hengrui Medicine's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received notification from the National Medical Products Administration approving the launch of its ω-3 triglyceride medium/long-chain fat emulsion/amino acid/glucose injection. This drug provides energy, essential fatty acids, amino acids, electrolytes, and fluids needed for parenteral nutrition therapy for adult patients with moderate to severe metabolic disorders. This news had a positive impact on the stock price but could not offset the overall market sentiment leading to a price decline. 2. On May 20, Goldman Sachs published a research report, continuing to prefer CDMO companies while selectively investing in pharmaceutical and biotechnology companies, focusing on deeper cooperation between Hengrui Medicine and multinational pharmaceutical companies. Despite the optimistic outlook in the report for Hengrui Medicine, the market reaction was lukewarm, and the stock price continued to decline. 3. On May 21, the Hong Kong innovative drug ETF Invesco received continuous net inflows of funds totaling HKD 57.6689 million over the past three days. Despite the capital inflow into the innovative drug sector, Hengrui Medicine's stock price did not benefit and continued to decline. The innovative drug sector shows high prosperity, with significant capital inflow. China National Pharmaceutical Group fell 1.14%. Based on recent news: 1. On May 21, China National Pharmaceutical Group and Boehringer Ingelheim jointly promoted the approval of Zongaitini tablets by the National Medical Products Administration for the first-line treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer with HER2 activating mutations This news had a positive impact on the stock price but failed to offset the overall market pressure, leading to a decline in the stock price. 2. On May 19, China Biologic Pharmaceutical spent HKD 10.0034 million to repurchase 1.89 million shares, demonstrating the company's confidence in its own stock. However, the market reaction was tepid, failing to significantly boost the stock price. 3. On May 22, clinical data for the innovative drug M701, jointly developed by a subsidiary of China Biologic Pharmaceutical, Zhengda Tianqing, was announced at the American Society of Clinical Oncology, showing significant efficacy in treating malignant ascites and malignant pleural effusion associated with non-small cell lung cancer. Although this news is favorable for the company's long-term development, it did not significantly impact the stock price in the short term. The overall market performance was weak, with noticeable capital outflows. **Stocks Ranked Among the Top in Industry Market Value** Hansoh Pharmaceutical fell by 1.41%. Based on recent news, 1. On May 21, Hansoh Pharmaceutical's self-developed fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor HS-10504 tablets were approved by the National Medical Products Administration of China for inclusion as a breakthrough therapy, with the intended indication for locally advanced or metastatic non-small cell lung cancer with EGFR C797S mutation after failure of EGFR-TKI treatment. This news boosted market confidence in the company's innovative drug development capabilities but did not significantly drive up the stock price. 2. On May 21, several innovative drugs from Hansoh Pharmaceutical participated in the medical insurance price reduction and simultaneously launched a charitable drug donation program, covering over 2 million low-income patients with chronic diseases and tumors. Although this move demonstrates the company's sense of social responsibility, the market expressed concerns about its short-term profitability, leading to a decline in the stock price. 3. On May 22, analysts gave Hansoh Pharmaceutical a latest rating of "Buy," with a target price of HKD 47. Despite analysts being optimistic about the company's prospects, the market reaction was muted, and the stock price did not significantly rebound. The market's response to innovative drug development and changes in medical insurance policies is complex ### Related Stocks - [07630.HK](https://longbridge.com/en/quote/07630.HK.md) - [01093.HK](https://longbridge.com/en/quote/01093.HK.md) - [01276.HK](https://longbridge.com/en/quote/01276.HK.md) - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) - [03692.HK](https://longbridge.com/en/quote/03692.HK.md) ## Related News & Research - [China's DSC reveals fall in 2025 revenue in US IPO filing](https://longbridge.com/en/news/287680122.md) - [Don't use AI when emailing Paul Graham](https://longbridge.com/en/news/287659485.md) - [How price variation impacts employers](https://longbridge.com/en/news/287666507.md) - [Dad jeans, big paychecks: hardware engineers are winning the AI boom](https://longbridge.com/en/news/287514213.md) - [Next-generation platforms poised to redefine crowded HAE landscape](https://longbridge.com/en/news/287658275.md)